Shares of Protagonist Therapeutics Inc (NASDAQ:PTGX) saw strong trading volume on Thursday . 898,218 shares were traded during trading, an increase of 342% from the previous session’s volume of 203,208 shares.The stock last traded at $13.65 and had previously closed at $13.21.

A number of research analysts recently issued reports on the company. BidaskClub upgraded Misonix from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 3rd. HC Wainwright set a $73.00 price objective on Uniqure and gave the company a “buy” rating in a research note on Monday. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. Stifel Nicolaus upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating and upped their price target for the stock from $11.00 to $17.00 in a research note on Wednesday, May 8th. Finally, ValuEngine upgraded VESTAS WIND SYS/ADR from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $17.17.

The company has a debt-to-equity ratio of 0.07, a current ratio of 5.02 and a quick ratio of 5.02. The firm has a market cap of $319.36 million, a price-to-earnings ratio of -7.84 and a beta of 1.88. The business has a 50 day moving average of $11.69.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.01. Protagonist Therapeutics had a negative return on equity of 40.78% and a negative net margin of 209.02%. The business had revenue of $1.56 million during the quarter, compared to the consensus estimate of $2.50 million. As a group, equities analysts anticipate that Protagonist Therapeutics Inc will post -2.36 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. Bank of Montreal Can boosted its stake in Protagonist Therapeutics by 1,675.5% in the 1st quarter. Bank of Montreal Can now owns 11,026 shares of the company’s stock worth $139,000 after purchasing an additional 10,405 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in shares of Protagonist Therapeutics by 75.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock worth $132,000 after acquiring an additional 8,450 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Protagonist Therapeutics by 94.3% during the 4th quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock worth $178,000 after acquiring an additional 12,819 shares in the last quarter. Tibra Equities Europe Ltd purchased a new stake in shares of Protagonist Therapeutics during the 1st quarter worth approximately $410,000. Finally, Northern Trust Corp raised its holdings in shares of Protagonist Therapeutics by 17.2% during the 4th quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock worth $234,000 after acquiring an additional 5,084 shares in the last quarter. Institutional investors and hedge funds own 64.40% of the company’s stock.

Protagonist Therapeutics Company Profile (NASDAQ:PTGX)

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Further Reading: Trading Strategy Methods and Types

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.